Replicate Bioscience has administered the first dosage of its RBI-4000 vaccine to a participant.

This article summarized the latest R&D progress of Norepinephrine Bitartrate, the Mechanism of Action for Norepinephrine Bitartrate, and the drug target R&D trends for Norepinephrine Bitartrate.

MEK, or Mitogen-Activated Protein Kinase Kinase, plays a crucial role in the human body as a key component of the MAPK signaling pathway.

This article summarized the latest R&D progress of Neostigmine Methylsulfate, the Mechanism of Action for Neostigmine Methylsulfate, and the drug target R&D trends for Neostigmine Methylsulfate.

Pierre Fabre Laboratories takes over Vertical Bio along with its ground-breaking, targeted therapy candidate for patients battling MET-altered Non-Small Cell Lung Cancer.

This article summarized the latest R&D progress of Milrinone Lactate, the Mechanism of Action for Milrinone Lactate, and the drug target R&D trends for Milrinone Lactate.

LSD1, also known as lysine-specific demethylase 1A, is an enzyme that plays a crucial role in the regulation of gene expression in the human body.

This article summarized the latest R&D progress of Midazolam Hydrochloride, the Mechanism of Action for Midazolam Hydrochloride, and the drug target R&D trends for Midazolam Hydrochloride.

Insilico Medicine and Exelixis, Inc. announced a licensing agreement allowing Exelixis to globally produce and market ISM3091, a promising USP1 inhibitor related to BRCA-altered cancers.

This article summarized the latest R&D progress of Metreleptin, the Mechanism of Action for Metreleptin, and the drug target R&D trends for Metreleptin.

Leukotriene antagonists work by blocking the action of leukotrienes, they are mainly used for preventing asthma, controlling allergic rhinitis or allergic reactions.

This article summarized the latest R&D progress of Lonafarnib, the Mechanism of Action for Lonafarnib, and the drug target R&D trends for Lonafarnib.